We report the case of a male patient with Ph-positive CML who developed AML 5 years after allogeneic BMT. Clinically, the AML seemed to develop on the basis of a myelodysplasia. The myeloid origin of blasts has been proven by immunophenotyping. The variable number of tandem repeats (VNTRs) and short tandem repeat (STR) showed donor-type haemopoiesis. The interphase FISH showed the XX genotype directly in the morphologically identifiable blasts and in the CD34-positive sorted bone marrow cells. This proved the new leukaemia to be of donor origin. The necessity of using multiple techniques and the advantage of combined immunophenotyping and FISH methods in this case is emphasized.
Allogeneic BMT is an effective treatment for haematological malignancies. However, with the improvement in survival, recipients of BMT have a significant risk for developing secondary malignancies, both solid tumours and haematological disorders. 1 The recurrence of leukaemia following allogeneic BMT remains one of the principal causes of treatment failure. Most leukaemia recurrences are relapses in host cells, usually as a regrowth of the original clone, but occasional reports have indicated leukaemia derived from cells of the donor. Donor cell leukaemia (DCL) was first described 30 years ago, when only cytogenetic study was available to confirm the cell origin. 2 Interphase studies, immunoglobulin allotyping and isoenzyme analysis were also useful to document host or donor involvement. [2] [3] [4] [5] More accurate results can be obtained if the traditional methods are combined with molecular studies such as reverse transcription-PCR (RT-PCR) analysis for bcr-abl transcripts and PCR amplification of several variable number tandem of repeats (VNTRs) or short tandem repeat (STR) to confirm the cell origin of leukaemia. [5] [6] [7] We report the case of a male patient with Ph chromosome and bcr-abl positive chronic phase chronic myeloid leukaemia who developed AML of donor origin 5 years after allogeneic BMT from his HLA-matched sister.
Case report
A 50-year-old man was diagnosed in December 1992 with Ph chromosome and b2a2 type bcr-abl-positive CML in first chronic phase. Treatment with IFN-␣ and hydroxyurea resulted in a stable chronic phase. He underwent an allogeneic BMT from his HLA-identical, MLC non-reactive sister in January 1996. Pretransplant conditioning regimen consisted of dibromomannitol (myelobromol) 40 mg/kg p.o. in divided doses daily for 3 days (total dose 120 mg/kg), and Ara-C 10 mg/kg twice daily i.v. for 3 days (total dose 60 mg/kg) and cyclophosphamide 50 mg/kg once daily i.v. for 3 days (total dose 150 mg/kg). 8 CsA and a short course of MTX were administered for prevention of GVHD. No acute GVHD developed. Immunosuppressive therapy was discontinued 4 months post transplant. He did well for 4 months (June 1996), when he developed a severe Pseudomonas pneumonia and an inferior myocardial necrosis thereafter. Recovering from these complications he remained in complete haematological and molecular remission repeatedly documented by negative results of RT-PCR analysis of the bcr-abl gene product. Traditional cytogenetic analysis of BM cells revealed exclusively normal female karyotype according to the donor. RBC grouping revealed only M+ donor-type cells. Based on VNTR analysis the peripheral blood cells showed complete donortype chimerism. The patient did well until July 2000 when he was admitted to the hospital with pancytopenia 4.5 years after BMT. Peripheral blood analysis revealed a WBC count of 1. the X chromosome were also seen. Combined analysis of pheno-and genotype has also been performed in order to verify whether the AML derived from the donor cells.
CD34
ϩ sorted marrow cells were used as an enriched leukaemic cell population and analysed by FISH using X and Y chromosome-specific probes. Two (or more) X chromosome-specific signals without Y chromosome-specific signals were detected in the nuclei of the CD34 ϩ sorted cells (Figure 2b) . PB (stored) smears were investigated for chromosomal aneuploidy by FISH using chromosome-specific (peri)centromeric probes for chromosomes 7 (p7tl), 8 (pJM128), 13/21 (Ll.26) and 20 (p3.4). Interphase cytogenetics revealed chromosome tetrasomy with all centromeric probes in 10-12% of the nuclei analysed, suggesting the presence of a minor tetrasomic component. RT-PCR analysis of PB and BM failed to detect a bcr-abl rearranged band. The presence of the bcr-abl fusion was also tested by FISH (Vysis, Downers Grove, IL, USA) to rule out a rare breakpoint position. 10 Out of the 259 nuclei analysed from the PB, 99 (23%) contained no fusion signal. Both the FISH analysis and RT-PCR confirmed the lack of the t(9;22) and bcr-abl chimeric gene. Hybridisation of the patient blood sample with the t(12;21) (TEL/AML1) probe (Vysis) showed no fusion signal in 225 out of 229 cells. RBC grouping did not show any change, Mϩ donor-type RBC was documented further. Based on VNTR (SE33) analysis donor-specific alleles were amplified exclusively both from the PB and BM obtained at the time of diagnosis of AML (Figure 2c) . 11 Furthermore, the STR-PCR analysis in the PB and BM with two microsatellite markers (chromosome 4 marker for locus D4S2366, chromosome 16 marker for locus D16S539) confirmed complete donor-specific allelic signals. 12 Based on the results of the methods used in this case the acute leukaemia appeared to be myeloid in type and derived from donor cells. Despite the severe findings in the BM the patient is in a good clinical state and requires only RBC transfusion support. No anti-leukaemia treatment has been initiated until now except dexamethasone which was given orally. The donor is very well and disease-free based on the normal BM morphology, immunophenotyping, and cytogenetic analysis.
Discussion
The development of new haematological malignancies following allogeneic BMT, particularly of donor origin, may provide some important clues to the nature of leukaemogenesis. During the last 15 years several studies have utilized molecular and molecular cytogenetic methods in combination with routine cytogenetic analysis to differentiate DCL from host leukaemia relapse. 5, 6 In the patient reported here the post-transplant secondary acute leukaemia appeared to be myeloid in type and derived from donor cells. The donor origin of haemopoiesis has been proved by the donor-type RBC blood group, the presence of XX sex chromosome, and the absence of the Ph chromosome in the BM cells both by traditional and interphase cytogenetic analysis. In addition, the VNTR and STR was exclusively donor specific and the bcr-abl RT-PCR was negative. Seventeen cases of DCL have previously been reported after BMT for leukaemia and two cases after transplant for benign disease. [2] [3] [4] [5] [6] [7] The 19 cases of DCL include 11 female and eight male patients with a median age of 19.6 years (range 3-43). The time interval from BMT to diagnosis of DCL ranged from 2 to 135 months (median 33 months). Four out of 19 DCLs developed in the first year after BMT, the other 15 ranged from 1 to 11 years post BMT. Five year or longer intervals post transplant were documented in three cases and in the case of the patient reported here. 3, 5 Our patient is the oldest compared with other patients known from the literature. Primary diagnosis of the DCL patients included ALL (n ϭ 7), CML (n ϭ 6), AML (n ϭ 4), SAA (n ϭ 1) and thalassaemia (n ϭ 1). DCL were AML in six and ALL in 13 patients. One patient and the case reported here developed AML in donor cells as transformation from myelodysplastic syndrome (MDS). However, the patient depicted here seems to differ from the case described by Lowsky et al 4 regarding the early transformation from RCMD to AML and absence of MDS-type cytogenetic abnormalities.
DCL could be defined by morphology, cytogenetics and immunophenotyping of malignant cells which differ from the initial leukaemia. Recently, molecular techniques have been used to verify the donor or host origin of leukaemia by their DNA VNTR or STR. 3, 5, 12 Combination of FISH with morphology or immunophenotyping seems to be a further diagnostic approach to determine the donor origin of leukaemia as has happened in this case. 3, 4 Cytogenetic abnormalities are known in de novo AML, MDS, secondary AML and DCL. In our patient, however, we did not find any chromosomal abnormality with traditional cytogenetic methods. Furthermore, this case demonstrates, through interphase cytogenetics using chromosome-specific centromeric probes for the somatic (7, 8, 13/21 and 20) and sex (X) chromosomes, the presence of the minor tetrasomic component in the leukaemic clone. The results imply that interphase cytogenetics might be more accurate as compared with metaphase analysis to reveal chromosomal aberrations in the nuclei of leukaemias. 9 DCLs appear to have an aggressive course and poor outcome. However, because of the small experience of reports, the optimal treatment of this disease is unknown. Dexamethasone alone was given to our patient and the leukaemia has not progressed during the last 6 months.
DCL has stimulated interest (despite its rarity) because of the expectation that it might provide insights into the aetiology and mechanisms of leukaemogenesis. Several hypotheses have been proposed to explain how DCL might arise. 5 One of them is that impaired immune surveillance might play a role in development of donor cell leukaemia. BMT is often accompanied by clinical immunodeficiency. 13 Several factors may contribute to defective immune responses in recipients: (1) transplant recipients may be unable to regenerate a complete new lymphocyte repertoire; (2) the graft may not contain a sufficient number and variety of self-renewing lymphoid progenitors; (3) the thymus may have involuted so that T cell maturation does not occur in the proper way; (4) immunosuppresssive drugs can initiate so-called iatrogenic immunodeficiency due to T cell abnormalities. 14 Immunodeficiency, especially T cell impairment predisposes the recipient to become susceptible to agents playing a role in malignant transformation of donor cells.
In conclusion, the need for accurate molecular diagnosis of DCL is clear and collection of further similar cases will bring us closer to understanding the pathogenesis of leukaemia. Donor cell leukaemia developed post transplant might serve as a model to study leukaemia development in vivo.
